ZBIO Stock Summary and Trading Ideas (Zenas Biopharma | NASDAQ:ZBIO)

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Zenas Biopharma trades on the NASDAQ stock market under the symbol ZBIO.

As of April 30, 2026, ZBIO stock price climbed to $19.32 with 644,190 million shares trading.

ZBIO has a beta of 0.87, meaning it tends to be less sensitive to market movements. ZBIO has a correlation of 0.01 to the broad based SPY ETF.

ZBIO has a market cap of $1.20 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ZBIO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

ZBIO has outperformed the market in the last year with a return of +72.5%, while the SPY ETF gained +31.0%. However, in the most recent history, ZBIO shares have underperformed the stock market with its stock returning -7.5% in the last 3 month period and -8.2% for the last 2 week period, while SPY has returned +3.8% and +2.7%, respectively.

ZBIO support price is $16.78 and resistance is $18.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZBIO shares will trade within this expected range on the day.